GLP-1 rebound: why weight can return when therapy stops
One of the most commonly reported findings in the GLP-1 literature is weight return after discontinuation. The biology behind it is important to understand upfront.
TL;DR
- The STEP-4 trial, published in JAMA in 2022, found that participants who discontinued semaglutide after 20 weeks regained a substantial portion of lost weight within the following year.
- The underlying mechanism involves appetite-regulating hormones and what researchers call body weight setpoint — the body’s tendency to defend a prior weight.
- This doesn’t make GLP-1 therapy ineffective; it reframes it as an ongoing management tool rather than a fixed-duration intervention for most people.
What it is
Weight rebound after stopping a GLP-1 receptor agonist refers to the documented pattern in which body weight increases again following discontinuation, often returning toward pre-treatment levels over a period of weeks to months. This is not specific to GLP-1 therapy — it is a well-characterized phenomenon in weight management research more broadly, sometimes called weight recidivism or post-intervention regain. What makes the GLP-1 data notable is the magnitude of the effect observed in controlled trial settings: the STEP-4 trial provided some of the clearest published documentation of this pattern in a randomized, placebo-controlled design.
How it works
GLP-1 receptor agonists suppress appetite through central nervous system signaling in the hypothalamus and brainstem. While on therapy, the body receives sustained pharmacological input that downregulates hunger signals. When that input stops, several compensatory mechanisms appear to activate. Appetite-stimulating hormones — particularly ghrelin — can increase following a period of caloric restriction. Simultaneously, the body’s energy expenditure may decrease, reflecting adaptation to the lower body weight. The concept of “body weight setpoint” in the obesity medicine literature describes how the brain tends to regulate energy intake and expenditure to defend a prior weight, particularly one maintained for an extended period.
Who asks about it
People come to this topic after either experiencing weight return themselves or reading about STEP-4 in the popular press and wondering whether GLP-1 therapy is worth starting if the gains aren’t retained. It’s also a question that comes up in honest clinical consultations: the clinician who explains the discontinuation data upfront is giving you material information, not a warning to avoid the therapy.
What the research says
The STEP-4 trial (Rubino et al., JAMA, 2022) enrolled participants who had achieved weight loss on semaglutide 2.4 mg weekly during a 20-week run-in phase, then randomized them to continued semaglutide or switched them to placebo. The semaglutide-continued group continued to lose weight; the placebo group regained approximately two-thirds of their previously lost weight by week 68. The study also documented rebound in cardiometabolic markers, waist circumference, and blood pressure in the discontinuation group. The authors concluded that for many individuals, continued therapy appears necessary to maintain the weight outcomes observed during active treatment.
What to know before considering it
This data is relevant to the clinical conversation you have before starting GLP-1 therapy. The evidence suggests that for many people, this is a long-term management approach rather than a short course. That has implications for how you plan — with your clinician — around monitoring, lifestyle behaviors, and the duration of any protocol. Any GLP-1 therapy requires a valid prescription and a licensed clinician evaluation. Compounded formulations are prepared by state-licensed 503A pharmacies and are not FDA-approved products.
The Halftime POV
The STEP-4 data isn’t a reason not to consider GLP-1 therapy — it’s a reason to understand what you’re signing up for. Weight management is a long-game clinical issue, not a short sprint. Knowing that discontinuation typically reverses the gains allows you to build a sustainable plan with a clinician instead of being caught off guard. That kind of informed starting point is exactly what the HH model is built around.
Related reading:
FAQ
Q: Does weight return after stopping GLP-1 therapy? A: Yes. The STEP-4 trial (Wilding et al., NEJM 2022) documented substantial weight return following semaglutide discontinuation — participants regained roughly two-thirds of their lost weight within one year of stopping. Appetite and body weight returned toward baseline as GLP-1 signaling was removed.
Q: Why does weight return when GLP-1 therapy stops? A: GLP-1 therapy suppresses appetite through continuous receptor signaling. When the drug is removed, the signaling stops, and appetite hormones — including ghrelin — rebound. The body’s weight setpoint and appetite regulatory systems reassert themselves. This is not a treatment failure; it reflects the biology of appetite regulation.
Q: What does this mean for long-term GLP-1 therapy? A: The STEP-4 withdrawal data suggests that GLP-1 therapy may need to be ongoing to maintain its effects, similar to other chronic condition treatments. The published literature does not support a finite ‘course’ model for most patients. This is a clinical conversation between patient and clinician based on individual goals, risks, and response.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Note on ongoing litigation: Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb. 2026). The regulatory landscape for compounded GLP-1 formulations continues to evolve.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Rubino DM, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity.” JAMA, 2022 (STEP-4)
- Sumithran P, et al. “Long-term persistence of hormonal adaptations to weight loss.” NEJM, 2011
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM, 2021 (STEP 1)
